Enrolling Clinical Studies
ALZEIMER'S DISEASE
(Early or Mild Cognitive Impairment)
This study will evaluate the efficacy, safety and tolerability of an intravenously administrated medication (BMS-986446) in participants with Early Alzheimer’s Disease or Mild Cognitive Impairment.
Requirements:
• Men or women between 50 to 80 years of age.
• Diagnosis of MCI due to AD for at least 1 year or Mild AD dementia.
• If receiving memory loss treatment (memantine) must be on a stable dose for 3 months.
• Must have a study partner to provide follow-up information on the participant.
• Subjects with a BMI between 17 and 35 kg/m2
• No history of Parkinson's disease, vascular dementia, hydrocephalus, seizures or intellectual disability.
• No subjects with major depression, schizophrenia, bipolar or chronic psychosis.
• No history of chronic medical condition (e.g., cardiac, respiratory, renal or gastrointestinal).
Study Duration:
This study contains a total of 17 in-clinic visits, 3 MRI and 1 PET Scan over a period of 44 weeks.
Compensation:
This study will pay $150 per in-clinic visit, and $50 per MRI.
Total approximate compensation up to $2,700 for completing the study
(same amount for the caregiver).